A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma
Status:
Completed
Trial end date:
2018-11-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess how the body handles olaratumab when it is given with
another drug called doxorubicin.
The safety and tolerability of these drugs will be studied. Each participant will complete
two 21-day cycles in a fixed order. Participants who complete Cycle 2 may continue to receive
olaratumab + doxorubicin for an additional six 21-day cycles and then may receive olaratumab
alone until discontinuation criteria are met.
Screening is required within 21 days prior to first dose.
Part B was added in October, 2015 to assess how the body handles a higher dose of olaratumab
when given with doxorubicin.
Participants may only enroll in one part.